During President Trump’s first term, the FDA gave the green light to GenBioPro, marking the debut of the first generic mifepristone. Fast forward six years, the FDA has approved a second generic through Evita Solutions.
It’s clear that the pro-life movement is keeping a close watch—not a mistake to think otherwise.
The recent approval of Evita Solutions’ abbreviated new drug application follows comments from Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty McCulley, who pledged to reassess the safety of brand-name Mifeprex. This move raises some questions, particularly about how the new generic mifepristone fits into efforts to “Make America Healthy Again.”
Kennedy, an advocate for this health agenda, seems to suggest that the FDA’s approval came amid some backlash against pro-life stances. He claims the agency acted correctly, stating that federal law mandates approval of generics if they’re identical to brand-name drugs.
Though he may have a point regarding the legal requirements, the reasoning feels a bit hollow and doesn’t really address the concerns being raised, especially those pushing to keep Mifeprex available.
Drugs that get the nod under this abbreviated application process depend heavily on the original brand’s clinical trials and safety history—Mifeprex in this case. According to federal regulations, the HHS Secretary can suspend or withdraw any drug approval if new information emerges suggesting the drug isn’t safe for its approved use.
In simpler terms, Kennedy and McCulley weren’t legally bound to keep mifepristone for sale, especially when significant safety worries have been highlighted by the Attorney General.
The Attorney General noted an analysis indicating that chemical abortions using mifepristone led to significantly more adverse events than reported during Mifeprex’s original approval. This raises serious eyebrows.
Given these findings, Kennedy would have had legitimate grounds to pause Mifeprex’s approval while a more thorough review took place, effectively overriding the legal constraints he mentioned regarding the approval of Evita Solutions’ application.
This hasty endorsement of a second generic mifepristone doesn’t really align with the high scientific standards Secretary Kennedy aspires for his office.
In a free market, introducing a second generic mifepristone is likely to ramp up competition, resulting in lower prices and greater access—objectives that align with many in the abortion movement.
Critics who claim reviews of mifepristone are unnecessary may miss the point. Past approvals involved not just positive reviews but also thorough assessments of risks.
While the FDA hasn’t confirmed a decision to keep the drug available, indicators suggest it might focus on reinstating risk assessment and mitigation strategies. However, that alone may not suffice, given the current landscape of distribution practices protected by existing laws. To really safeguard women, the only effective course would be to fully revoke mifepristone’s approval for chemical abortions.
The Trump administration will likely face legal challenges from various factions within the abortion rights community. But considering Trump’s history, litigation threats haven’t usually deterred his team. It’s well within the FDA’s rights to take immediate actions regarding mifepristone while conducting its official review.
